Literature DB >> 17721920

Activation of AKT and nuclear accumulation of wild type TP53 and MDM2 in anal squamous cell carcinoma.

Heena Patel1, Guadalupe Polanco-Echeverry, Stefania Segditsas, Emmanouil Volikos, Amy McCart, Cecilia Lai, Thomas Guenther, Abed Zaitoun, Oliver Sieber, Mohammed Ilyas, John Northover, Andrew Silver.   

Abstract

Human papilloma virus (HPV) infection is considered as an important aetiological factor for anal squamous cell carcinoma (ASCC) but is not sufficient for tumour progression. This carcinoma is poorly understood at the molecular level. Using the largest cohort of cases to date we investigated the molecular mechanisms underlying ASCC development, in particular the roles of TP53, MDM2 and AKT. Viral infection in our cohort occurred at high frequency (73%, 94/128) with HPV16 accounting for the majority (86%, 81/94) of infected cases. Only 4% (5/119) of ASCCs showed TP53 (exons 5-8) mutations, but a high frequency (91%, 100/110) of nuclear protein expression of TP53 was observed. There was a significant association (p < 0.001) between nuclear accumulation of TP53 and MDM2 protein although no MDM2 mutations were found, and copy number was normal. Cellular accumulation of phosphorylated-AKT was observed in 66% (82/125) of ASCCs and an association demonstrated between nuclear accumulation of MDM2 and activated AKT (p < 0.001). We observed a high frequency of copy number gain at PIK3CA (47%), and some coding sequence mutations (4%). Amplification of PIK3CA was associated with presence of phosphorylated-AKT (p= 0.008). There was no association between virus infection and TP53 nuclear accumulation (p = 0.5). However, a significant association was found between infection and MDM2 nuclear staining, and between infection and activated AKT (p = 0.04, p = 0.01, respectively). We propose that activation of AKT, possibly through the PI3K-AKT pathway, is an important component of ASCC tumorigenesis that contributes to MDM2 and TP53 accumulation in the nucleus. (c) 2007 Wiley-Liss, Inc.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17721920     DOI: 10.1002/ijc.23028

Source DB:  PubMed          Journal:  Int J Cancer        ISSN: 0020-7136            Impact factor:   7.396


  12 in total

1.  Curcumin inhibits proliferation of colorectal carcinoma by modulating Akt/mTOR signaling.

Authors:  Sara M Johnson; Pat Gulhati; Isela Arrieta; Xiaofu Wang; Tatsuo Uchida; Tianyan Gao; B Mark Evers
Journal:  Anticancer Res       Date:  2009-08       Impact factor: 2.480

2.  Phase II Study of Capecitabine in Substitution of 5-FU in the Chemoradiotherapy Regimen for Patients with Localized Squamous Cell Carcinoma of the Anal Canal.

Authors:  Suilane Coelho Ribeiro Oliveira; Camila Motta Venchiarutti Moniz; Rachel Riechelmann; Alexandra Kichfy Alex; Maria Ignez Braghirolli; Giovanni Bariani; Caio Nahas; Paulo Marcelo Gehm Hoff
Journal:  J Gastrointest Cancer       Date:  2016-03

3.  A mouse model for human anal cancer.

Authors:  Marie K Stelzer; Henry C Pitot; Amy Liem; Johannes Schweizer; Charles Mahoney; Paul F Lambert
Journal:  Cancer Prev Res (Phila)       Date:  2010-10-06

4.  Molecular characterization of squamous cell carcinoma of the anal canal.

Authors:  Mohamed E Salem; Benjamin A Weinberg; Samantha A Armstrong; Rita Malley; Hongkun Wang; Heinz-Josef Lenz; David Arguello; Wafik S El-Deiry; Joanne Xiu; Zoran Gatalica; Jimmy J Hwang; Philip A Philip; Anthony F Shields; John L Marshall
Journal:  J Gastrointest Oncol       Date:  2021-10

Review 5.  The role of the PI3K/Akt/mTOR signalling pathway in human cancers induced by infection with human papillomaviruses.

Authors:  Lifang Zhang; Jianhong Wu; Ming Tat Ling; Liang Zhao; Kong-Nan Zhao
Journal:  Mol Cancer       Date:  2015-04-17       Impact factor: 27.401

6.  Inhibition of mTOR reduces anal carcinogenesis in transgenic mouse model.

Authors:  Zhi-Jun Sun; Lu Zhang; Wei Zhang; Bradford Hall; Yansong Bian; Ashok B Kulkarni
Journal:  PLoS One       Date:  2013-10-04       Impact factor: 3.240

Review 7.  Research on Anal Squamous Cell Carcinoma: Systemic Therapy Strategies for Anal Cancer.

Authors:  Ryan M Carr; Zhaohui Jin; Joleen Hubbard
Journal:  Cancers (Basel)       Date:  2021-05-01       Impact factor: 6.639

8.  Mutational analysis of anal cancers demonstrates frequent PIK3CA mutations associated with poor outcome after salvage abdominoperineal resection.

Authors:  Wulfran Cacheux; Etienne Rouleau; Adrien Briaux; Petros Tsantoulis; Pascale Mariani; Marion Richard-Molard; Bruno Buecher; Virginie Dangles-Marie; Sophie Richon; Julien Lazartigues; Emmanuelle Jeannot; Fereshteh Farkhondeh; Xavier Sastre-Garau; Anne de La Rochefordière; Alain Labib; Marie-Christine Falcou; Denise Stevens; Arnaud Roth; Sergio Roman-Roman; Emmanuel Mitry; Ivan Bièche; Astrid Lièvre
Journal:  Br J Cancer       Date:  2016-05-24       Impact factor: 7.640

9.  Comprehensive multiplatform biomarker analysis of 199 anal squamous cell carcinomas.

Authors:  Brandon G Smaglo; Anteneh Tesfaye; Thorvardur R Halfdanarson; Joshua E Meyer; Jue Wang; Zoran Gatalica; Sandeep Reddy; David Arguello; Patrick M Boland
Journal:  Oncotarget       Date:  2015-12-22

Review 10.  Immune Checkpoint Modulation in Colorectal Cancer: What's New and What to Expect.

Authors:  Julie Jacobs; Evelien Smits; Filip Lardon; Patrick Pauwels; Vanessa Deschoolmeester
Journal:  J Immunol Res       Date:  2015-10-29       Impact factor: 4.818

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.